Antibody Target, Technology & Pipeline Database: 1-Year Subscription
|発行||La Merie Publishing||商品コード||276495|
|抗体標的・技術・パイプラインデータベース：1年定期購読 Antibody Target, Technology & Pipeline Database: 1-Year Subscription|
|出版日: 年間契約型情報サービス||ページ情報: 英文||
Therapeutic monoclonal antibodies have become a clinically and commercially successful class of drugs. Branded therapeutic antibodies on the market reached global sales of US$ 91.5 bln in the year 2015, with a growth rate of 11.3% compared with the previous year. Despite the emergence of biosimilar antibodies due to patent expiries, validation of new targets, such as immune checkpoint moleucles, and of new antibody technologies enable the generation of innovative and IP-protected antibodies fostering further growth of the therapeutic antibody market. Among the enabling antibody technologies are
These technologies also allow to revisit so far unsuccessful antibody targets. Immuno-oncology is one of the most dynamic R&D fields in the industry, so far mainly based on immune checkpoint inhibitor antibodies targeting PD-1 and PD-L1 alone and in combination with a vast variety of other approaches for cancer therapy.
Subscription to La Merie Publishing's proprietary Antibody Database provides -as of April 2016 - online access to information about more than 3,400 project entries for therapeutic antibodies on the market and in research & development. Pre-established and free search functions allow to identify antibodies according to their
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antidoies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
Purchase of the subscription provides a 1-year online access to the data of the Antibody Target, Technology & Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the Antibody Pipeline Database: